Impressive Sales Growth for Cresemba™ in Europe
Basilea Pharmaceutica Ltd has shared exciting news about its antifungal medication, Cresemba™ (isavuconazole). Sales of this drug, which is marketed in Europe through its licensing partner Pfizer, have exceeded expectations, leading to a significant milestone payment of USD 25 million to Basilea. This impressive performance not only highlights the rising demand for effective antifungal treatments but also underscores Basilea's commitment to meeting the urgent medical needs of patients battling serious fungal infections.
CEO's Insights on Sales Success
David Veitch, the CEO of Basilea, expressed his enthusiasm regarding the ongoing success of Cresemba. He remarked, “We are very pleased with the continued recognition of Cresemba in addressing the critical medical needs of patients with life-threatening invasive mold infections. The growth in sales performance in Europe has directly led to this milestone payment.” Veitch also pointed out several previous milestone payments from sales in the Asia Pacific region and China, emphasizing Cresemba's global success.
Extensive Market Reach
Basilea’s strategic licensing agreement with Pfizer covers not only Europe (excluding the Nordic countries) but also includes 16 countries in the Asia Pacific region and China. This broad reach enhances the accessibility of Cresemba, which is approved for use in over 70 countries worldwide. Major markets such as the United States and various EU nations have significantly contributed to the reported global sales, which reached USD 489 million for the twelve months ending March 2024.
About Cresemba™ and Isavuconazole
Isavuconazole, known as Cresemba™, is an innovative azole antifungal that comes in both intravenous and oral forms. It is a vital treatment option for invasive fungal infections, particularly for conditions like invasive aspergillosis and mucormycosis. Basilea has secured multiple licensing agreements for isavuconazole across approximately 115 countries, ensuring its availability in various healthcare systems. In the EU, isavuconazole is approved for patients as young as one year old, highlighting its significance in pediatric care as well.
The Mission of Basilea Pharmaceutica
Founded in 2000 and based in Switzerland, Basilea is dedicated to discovering and commercializing novel therapeutics aimed at treating severe infections caused by bacteria and fungi. The company has successfully launched two main products: Cresemba for fungal infections and Zevtera for bacterial infections. Additionally, Basilea boasts a diverse portfolio that includes several preclinical and clinical anti-infective compounds, reinforcing its commitment to addressing critical healthcare needs.
Contact Basilea for More Information
If you would like to learn more about Basilea and its offerings, please find the contact details below:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd
Hegenheimermattweg 167b
4123 Allschwil, Switzerland
Phone: +41 61 606 1102
Email: media_relations@basilea.com | investor_relations@basilea.com
Frequently Asked Questions
What is Cresemba™ used for?
Cresemba™ is an antifungal medication used to treat serious infections such as invasive aspergillosis and mucormycosis.
Who is the licensing partner for Cresemba™ in Europe?
Pfizer is the licensing partner responsible for distributing Cresemba™ in Europe.
How much was the recent milestone payment to Basilea?
Basilea received a milestone payment of USD 25 million after exceeding sales thresholds for Cresemba™.
In how many countries is Cresemba™ approved?
Cresemba™ is approved in more than 70 countries around the world.
What are the primary focuses of Basilea Pharmaceutica?
Basilea is focused on developing and commercializing innovative treatments for severe bacterial and fungal infections.
